The open-label Phase 3b TOGETHER-PsO trial evaluated Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in plaque psoriasis patients with obesity. The combo arm achieved 27.1% PASI 100 and ≥10% weight loss compared to 5.8% on monotherapy, and delivered a 40% relative increase in PASI 100 rates (40.6% vs 29%). Common adverse events in the combo arm included nausea, diarrhea, constipation, injection site reactions, dosing errors, vomiting and dizziness.

Eli Lilly granted CSL exclusive global rights to develop and commercialize clazakizumab for preventing cardiovascular events in end-stage kidney disease (ESKD). The agreement includes a $100 million upfront payment to Lilly plus potential clinical, regulatory and commercial milestone payments, as well as royalties on net sales, while Lilly retains rights for additional indications.

Lilly shares trade 2.7% below their 20-day SMA and 3.2% below their 50-day SMA, but remain 4.3% above the 100-day and 17.6% above the 200-day averages, with RSI at 48.22 and a bearish MACD. The average analyst price target stands at $1,141.70, with Deutsche Bank raising its target to $1,285, JP Morgan to $1,300 and Cantor Fitzgerald to $1,205, all maintaining Buy or Overweight ratings.

Jim Cramer highlighted that Lilly has picked up share points against Novo Nordisk following manufacturing issues at Novo, noting growing momentum for Lilly’s Mounjaro injection and the emerging appeal of an oral weight loss pill, which he said could drive further market uptake.